Total submissions: 2
Submitter | RCV | SCV | Clinical significance | Condition | Last evaluated | Review status | Method | Comment |
---|---|---|---|---|---|---|---|---|
Counsyl | RCV000673281 | SCV000798465 | uncertain significance | Maple syrup urine disease | 2018-03-12 | criteria provided, single submitter | clinical testing | |
Labcorp Genetics |
RCV000673281 | SCV002236432 | pathogenic | Maple syrup urine disease | 2021-11-15 | criteria provided, single submitter | clinical testing | For these reasons, this variant has been classified as Pathogenic. This variant disrupts a region of the DBT protein in which other variant(s) (p.Arg462Pro) have been determined to be pathogenic (PMID: 11112664, 26232051). This suggests that this is a clinically significant region of the protein, and that variants that disrupt it are likely to be disease-causing. ClinVar contains an entry for this variant (Variation ID: 557174). This premature translational stop signal has been observed in individual(s) with maple syrup urine disease (PMID: 30228974). It has also been observed to segregate with disease in related individuals. This variant is not present in population databases (gnomAD no frequency). This sequence change creates a premature translational stop signal (p.Ser461*) in the DBT gene. While this is not anticipated to result in nonsense mediated decay, it is expected to disrupt the last 22 amino acid(s) of the DBT protein. |